新型预制可活动间隔物在二期假体周围感染治疗中的并发症与结局
BACKGROUND: Various prefabricated articulating spacer options have been described for 2-stage treatment of chronic periprosthetic joint infection, but their results are poorly generalizable between designs due to differing antibiotic and material properties.…
要点
- 间隔物至再植入期间无骨折、不稳或植入物相关并发症,生存率100%。
- 84.6%的切除关节实现再植入,再植入后需辅助器械者从67%降至31%。
- 膝关节屈曲从切除前平均88.1°改善至再植入后111.9°。
核心结论
- 新型预制可活动抗生素间隔物安全,允许良好的间隔期功能,早期随访感染清除率合理。
主要发现
- 间隔物无骨折、不稳或其他植入物相关并发症直至再植入的生存率为100%。
- 再植入率为84.6%,间隔期及再植入时无骨或间隔物骨折。
- 间隔物植入后除1例外均允许负重,需辅助器械者从切除前67%降至再植入后31%。
- 膝关节屈曲从切除前平均88.1°改善至再植入后111.9°。
关键数值与推荐
- 间隔物生存率(无骨折、不稳或其他植入物相关并发症直至再植入)为100%。
- 膝关节屈曲平均从88.1°改善至111.9°,需辅助器械比例从67%降至31%。
临床怎么用
- 该预制可活动间隔物可用于慢性假体周围感染的二期治疗,允许间隔期负重并维持关节功能。
局限性
- 回顾性设计,证据等级为治疗性III级,随访时间较短(平均16.6±10.4个月)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Various prefabricated articulating spacer options have been described for 2-stage treatment of chronic periprosthetic joint infection, but their results are poorly generalizable between designs due to differing antibiotic and material properties. This study reports outcomes for a novel, prefabricated, commercially available cement-on-cement articulating spacer. METHODS: A retrospective review of prospectively collected data for patients undergoing treatment with a prefabricated articulating cement spacer was performed. Outcomes were categorized as spacer complications, reimplantation rates, function, reinfection, and mortality. RESULTS: Seventy-six knees and 28 hips were analyzed. Spacer survival free of fracture, instability, or other implant-related complication until reimplantation was 100%. There were no bony or spacer fractures during the interstage or reimplantation. Reimplantation occurred in 84.6% of resected joints. Following spacer implantation, all but 1 patient was allowed to bear weight. The proportion of patients requiring an assistive device decreased from 67% prior to resection to 31% following reimplantation. Knee flexion improved from an average of 88.1° before resection to 111.9° following reimplantation. Eighty-seven percent of cases were infection free at mean follow-up of 16.6 ± 10.4 months. CONCLUSION: Study results demonstrate that this novel, prefabricated, articulating antibiotic spacer is safe, allows for good interstage function, and results in reasonable infection eradication rates at early term follow-up. LEVEL OF EVIDENCE: Therapeutic Level III.
引用
- Buller LT, Ziemba-Davis M, Meneghini RM, et al. Complications and Outcomes Associated With a Novel, Prefabricated, Articulating Spacer for Two-Stage Periprosthetic Joint Infection Treatment. J Arthroplasty. 2021. PMID: 34518057. doi:10.1016/j.arth.2021.08.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。